Molecular imaging and biology, 2022-12, Vol.24 (6), p.853-861
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Pilot Study: PARP1 Imaging in Advanced Prostate Cancer
- Ist Teil von
- Molecular imaging and biology, 2022-12, Vol.24 (6), p.853-861
- Ort / Verlag
- Cham: Springer International Publishing
- Erscheinungsjahr
- 2022
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Purpose PARP inhibitor (PARPi) therapy is approved for patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) genomic aberrations. However, only a fraction of patients with BRCA1/2 mutations respond to PARPi therapy. In this pilot study, we assess PARP-1 expression in prostate cancer patients with and without HRR genomic alternations using a novel PARP-based imaging agent. Procedures Nine advanced prostate cancer patients were studied with PET/CT and [ 18 F]FluorThanatrace (FTT), an analogue of the PARPi rucaparib. Images were analyzed using maximum standardized uptake values (SUV max ). PARP expression was assessed by immunohistochemistry (IHC) when feasible ( n = 4). Results We found great variability in FTT uptake (SUV max range: 2.3–15.4). Patients with HRR mutations had a significantly higher SUV max ( p = 0.0379) than patients with non-HRR mutations although there was an overlap in FTT uptake between groups. Three patients without HRR and one with HRR mutations had similarly high PARP1 IHC expression. Conclusions FTT-PET/CT may serve as an alternate biomarker for PARP1 expression and a potential method for PARPi treatment selection.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1536-1632eISSN: 1860-2002DOI: 10.1007/s11307-022-01746-wTitel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9681698
- Format
- –
- Schlagworte
- Alternations, Antineoplastic Agents - pharmacology, Biomarkers, BRCA1 protein, Brief, Brief Article, Castration, Computed tomography, Genomics, Homologous recombination, Homologous recombination repair, Humans, Imaging, Immunohistochemistry, Male, Medical imaging, Medicine, Medicine & Public Health, Metastases, Mutation, Patients, Pilot Projects, Poly (ADP-Ribose) Polymerase-1 - genetics, Poly(ADP-ribose) polymerase, Poly(ADP-ribose) Polymerase Inhibitors - pharmacology, Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use, Positron emission, Positron Emission Tomography Computed Tomography, Prostate cancer, Prostatic Neoplasms - diagnostic imaging, Prostatic Neoplasms - genetics, Prostatic Neoplasms - pathology, Radiology